About ElevateBio
ElevateBio is a company based in Cambridge (United States) founded in 2018 by David Hallal.. ElevateBio has raised $1.25 billion across 4 funding rounds from investors including Fidelity Investments, Novo Nordisk and ITOCHU. The company has 309 employees as of December 31, 2021. ElevateBio has completed 1 acquisition, including LifeEDIT. ElevateBio offers products and services including cGMP Manufacturing, Gene Editing Platform, and Process Development. ElevateBio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Employees 309 as on 31 Dec, 2021
- Founders David Hallal
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Elevatebio Management, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.25 B (USD)
in 4 rounds
-
Latest Funding Round
$401 M (USD), Series D
May 24, 2023
-
Investors
Fidelity Investments
& 17 more
-
Employee Count
309
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ElevateBio
ElevateBio offers a comprehensive portfolio of products and services, including cGMP Manufacturing, Gene Editing Platform, and Process Development. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides advanced manufacturing for cell and gene therapies
Enables precise gene editing for therapeutic applications
Supports optimization of therapy production processes
Unlock access to complete
Unlock access to complete
Funding Insights of ElevateBio
ElevateBio has successfully raised a total of $1.25B across 4 strategic funding rounds. The most recent funding activity was a Series D round of $401 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $401.0M
-
First Round
First Round
(13 May 2019)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series D - ElevateBio | Valuation | Matrix Capital Management | |
| Mar, 2021 | Amount | Series C - ElevateBio | Valuation | Matrix Capital Management | |
| Mar, 2020 | Amount | Series B - ElevateBio | Valuation | Invus , Citadel |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ElevateBio
ElevateBio has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Novo Nordisk and ITOCHU. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ElevateBio
ElevateBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LifeEDIT. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapy therapeutics are developed via genome editing platforms.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ElevateBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Elevatebio Comparisons
Competitors of ElevateBio
ElevateBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Elevatebio
Frequently Asked Questions about ElevateBio
When was ElevateBio founded?
ElevateBio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is ElevateBio located?
ElevateBio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is ElevateBio a funded company?
ElevateBio is a funded company, having raised a total of $1.25B across 4 funding rounds to date. The company's 1st funding round was a Series B of $170M, raised on May 13, 2019.
How many employees does ElevateBio have?
As of Dec 31, 2021, the latest employee count at ElevateBio is 309.
What does ElevateBio do?
Provider of transnational research for portfolio of cell and gene therapy. It offers transformative therapy along with other translational research like process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.
Who are the top competitors of ElevateBio?
ElevateBio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does ElevateBio offer?
ElevateBio offers cGMP Manufacturing, Gene Editing Platform, and Process Development.
How many acquisitions has ElevateBio made?
ElevateBio has made 1 acquisition, including LifeEDIT.
Who are ElevateBio's investors?
ElevateBio has 18 investors. Key investors include Fidelity Investments, Novo Nordisk, ITOCHU, Citadel, and SoftBank Vision Fund.